Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrexafungerp Tablets for Vulvovaginal Candidiasis in Chinese Adults
CTR20220918Phase 3Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Apr 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ibrexafungerp in vulvovaginal candidiasis (VVC), sponsored by SCYNEXIS, Inc.. Started Apr 2022; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on CTR20220918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220918.